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1INTRODUCTION
Schizophrenia is a type of functional psychoses in which severe
personality changes and thought disorders occur with no evidence of organic
cerebral damage. Although improvement is seen over a prolonged period of time
for some patients, most of the patients experience some persisting symptoms
despite treatment (1). To prevent relapse, maintenance treatment with
antipsychotic drugs is obligatory for most patients who have schizophrenia. (2)
Antipsychotic drugs are the cornerstone for the treatment of schizophrenia.
First-generation antipsychotics, such as haloperidol, which mainly have
dopamine D2 antagonist action, are effective against positive symptoms, but they
are relatively less beneficial in treating negative and associated mood symptoms.
(3) In addition, the D2 antagonists frequently induce extrapyramidal side effects
(e.g., parkinsonism, dystonia, akathisia, and tardive dyskinesia) that are thought
to reflect blockade of D2 receptors in the basal ganglia(4).
Second-generation antipsychotics, which commonly have combined 5-
hydroxytryptamine 2A (5- HT2A) and D2 blocking activity, may offer greater
improvement in negative symptoms (5) , and have a more favorable tolerability
profile with markedly reduced risk of EPS. However, several second-generation
antipsychotics (e.g., clozapine, olanzapine) are associated with significant
weight gain and metabolic dysfunction (6). Most of the atypical antipsychotics
have relatively high affinity for α1 receptors, muscarinic receptors &
H1 receptors. Some of the atypical antipsychotics produce weight gain, sedation
and impairment in cognitive function by acting at these receptors (7)
2Results from randomized, large, double-blind study showed that majority
of chronic schizophrenia patients withdrawn their antipsychotic medications,
because of either lack of efficacy of drug or intolerable adverse drug reactions (8).
Considering these drawbacks we need a drug with good clinical efficacy and
lower or absent extrapyramidal and metabolic side effects.
Lurasidone is an atypical antipsychotic drug recently approved in India apart
from other countries for the treatment of schizophrenia. It blocks D2, 5-HT2A and
5-HT7 receptors. It has partial agonistic activity on 5-HT1A receptor but has no
effect on H1 and muscarinic receptors. As it has negligible activity at H1 and 5-
HT2C receptors, lurasidone may produce lesser incidence of weight gain. The
sedation is low due to very minimal action on H1 receptors.
Risperidone is the second generation antipsychotic that gained approval
of the Food and Drug Administration in 1994 and since then it is gaining rapid
popularity. There are various studies which provide evidences that risperidone is
as effective as second generation antipsychotics in treating positive symptoms
and more effective in treatment of negative symptoms(10).
This study is intended to find the clinical efficacy and safety profile of
lurasidone comparing with risperidone, a drug in common use nowadays.
3REVIEW OF LITERATURE
SCHIZOPHRENIA - HISTORY
It is very clear that psychotic disorders have been present and publicly
recognized since ancient times because of their portrayals in old literatures like
the madness of medea and the paranoia of Othello. Among the psychotic
disorder schizophrenia is the most common disorder and devastating mental
illness that affects 1% of population across all cultures (11).
The ancient Greeks took a great interest in the human psyche and
especially in madness. Plato who lived in the 5th and 4th centuries BC speaks
about two kinds of madness, one with a divine origin and another with a physical
origin. His descriptions on madness of divine origin closely coincide with the
modern descriptions of schizophrenia (12).
The influence from Hippocrates is obvious in the citation from
Problemata. Hippocrate, the ‘father of medicine’, was partly a contemporary
with Plato. He thought that the origin of the diseases as a disturbance of the
balance of the humours that is the body fluids. This model groups the humours
into blood, phledge, yellow bile and black bile. According to the humoural
pathology, an imbalance of the body fluids may influence the brain and provoke
madness (13).
The earliest academic formulations of the concept of schizophrenia
started in the mid-nineteenth century, especially in the work of Benedict-
Auguste Morel and Karl Kahlbaum. Morel coined the term ‘demence precoce’ to
4refer to a disorder that he observed in young people that was characterized by
cognitive impairments associated with progressive degeneration (14). Kahlbaum’s
contribution was based on course of illness as opposed to symptoms to define
discrete disorders. He objected to the concept of unitary psychosis coined by
Greisinger that there was only one form of severe mental illness and argued that
various kinds of psychotic disorders could be differentiated from one another
based on changing patterns of symptoms and long-term outcome. Kahlbaum
identified one type of such mental illness as ‘hebephrenia’ which was later
included in main classification as a subtype of schizophrenia.
Emil Kraepelin was clearly the first to give a detailed description of this
syndrome and contributed much to the modern concept of schizophrenia.
Kraepelin described schizophrenia as an illness that tended to begin at an early
age (‘praecox’) and to have a relatively chronic course characterized by
significant cognitive and social impairment (‘dementia’) ( 15) . Bleuler was a near
contemporary of Kraepelin. Bleuler wanted to highlight fragmenting of thinking
as the most fundamental feature of schizophrenia and designated it as the
pathognomonic symptom. He named this particular symptom as ‘loosening of
associations’ was present in all patients with schizophrenia and did not occur in
other disorders. Because of the importance that he gave to this particular
symptom, he renamed the illness and coined the term schizophrenia means
fragmenting of mind. Students of schizophrenia used Bleuler’s name for the
disorder and defined it in terms of the four ‘A’s (associations, autism, affect, and
ambivalence).
5In the late 1960s and 1970s Bleulerian concept began to change. Bleuler’s
secondary or accessory symptoms began to be treated as the pathognomonic
symptoms. The emphasis on florid psychotic symptoms arose because of the
influence of Kurt Schneider (16). Schneider, like Bleuler, wished to explore
symptoms that were fundamental. He concluded that one critical component was
an inability to find the boundaries between self and not-self and a loss of the
sense of personal autonomy. This led him to discuss various ‘first-rank’
symptoms that were characterized by this loss of autonomy, such as thought
insertion or delusions of being controlled by outside forces (17, 18). Schneider
considered first rank symptoms were strongly indicative of schizophrenia in the
absence of overt brain disease.
Schneider’s first rank symptoms of schizophrenia
 Voices commenting—a hallucinatory voice commenting on one’s actions
in the third person
 Voices discussing or arguing—hallucinations of two or more voices
discussing or arguing about oneself
 Audible thought—hearing one’s thoughts aloud
 Thought insertion—the insertion, by an alien sources, of thoughts that are
experienced as not being one’s own
 Thought withdrawal—the withdrawal of thoughts from one’s mind by an
alien agency
 Thought broadcast—the experience that one’s thoughts are broadcast so
as to be accessible to others
6 Made will—the experience of one’s will being controlled by an alien
influence
 Made acts—the experience that acts executed by one’s own body are the
actions of an alien agency, rather than oneself
 Made affect—the experience of emotion that is not one’s own, attributed
to an alien influence
 Somatic passivity—bodily function is controlled by an alien influence
 Delusional perception—the attribution of a totally unwarranted meaning
to a normal perception
Neither Kraepelin nor Bleuler actually used the terms ‘positive symptoms’ or
‘negative symptoms’, although the concepts are embedded in their writings.
While various sources for this term can be cited, one of the earliest and most
prominent was Hughlings- Jackson (19). Jackson believed that some symptoms
represented a relatively pure loss of function (negative symptoms), while
positive symptoms such as delusions and hallucinations represented an
exaggeration of normal function and might represent release phenomena.
In his famous two syndrome hypothesis theory of schizophrenia (20), Crow
proposed that schizophrenia could be divided into two different syndromes,
which he referred to as Type I and Type II. Type I schizophrenia was
characterized by prominent positive symptoms, an acute onset, good premorbid
adjustment, a good response to treatment, intact cognition, intact brain structure,
and an underlying mechanism that was neurochemical (dopaminergic) and
therefore reversible.
7Type II schizophrenia was characterized by prominent negative
symptoms, an insidious onset, poor premorbid adjustment, a poor response to
treatment, impaired cognition, structural brain abnormalities like ventricular
enlargement in CT brain and an underlying mechanism that was characterized by
neuronal loss and therefore irreversible. Although the distinction between
positive and negative implied in the two syndrome hypothesis might be
misleading, it was useful to recognize that some symptoms tend to get patients
hospitalized and to call these ‘positive’ and that other symptoms tend to lead to
psychosocial morbidity and to call these ‘negative’.
By the time that DSM-IV (21) and ICD-10(22) were written, the concept of positive
and negative symptoms was so widely accepted that negative symptoms were
included in their diagnostic criteria for the first time.
Diagnosis and classification of schizophrenia
Throughout the 1970s and early 1980s there was an overabundance of
criteria including the St. Louis criteria (23) and the Research Diagnostic Criteria
(24), followed by the Present State Examination, the ICD-9, and the DSM-III.
Currently the most refined criteria we are using Diagnostic statistical manual-V
(DSM-V) and International classification of disease, 10th version (ICD-10).
8DSM-5 diagnostic criteria for schizophrenia(25)
A. ≥2 of the following, each present for a significant duration during 1 month
period of time (or less if successfully treated). At least one of the following must
be (1), (2), or (3):
1) Delusions.
2) Hallucinations.
3) Disorganized speech (frequent derailment / incoherence).
4) Grossly disorganized or catatonic behavior.
5) Negative symptoms (diminished emotional expression / avolition).
B. For a significant duration since the onset of the disturbance, level of
functioning in one or more major areas like work, self-care or interpersonal
relations is markedly reduced below the level than prior to the onset (or when the
onset is in early childhood or adolescent period, failure to achieve the expected
level of academic, interpersonal, or occupational functioning).
C. Continuous signs of the disturbance persist for at least six months. This 6
month period must include at least one month of symptoms (or less if
successfully treated) that meet Criterion A (ie, active-phase symptoms) and may
include periods of prodromal or residual symptoms. During these prodromal or
residual periods, the signs of the disturbance may be manifested by only negative
symptoms or by two or more symptoms listed in Criterion A present in an
attenuated form (eg, odd beliefs, unusual perceptual experiences).
D. Schizoaffective disorder and depressive or bipolar disorder with psychotic
features have been ruled out because either 1) no major depressive or manic
9episodes have occurred concurrently with the active-phase symptoms, or 2) if
mood episodes have occurred during active-phase symptoms, they have been
present for a minority of the total duration of the active and residual periods of
the illness.
E. The disturbance is not attributable to the direct physiological effects of a
substance (eg, a drug of abuse, a medication) or another medical condition.
F. If there is a history of autism spectrum disorder or a communication disorder
of childhood onset, the additional diagnosis of schizophrenia is made only if
prominent delusions or hallucinations, in addition to the other required
symptoms of schizophrenia, are also present for at least one month (or less if
successfully treated).
ICD 10 criteria for schizophrenia(26)
The normal requirement for a diagnosis of schizophrenia is that a minimum
of one very clear symptom (and usually two or more if less clear-cut)
belonging to any one of the groups listed as (a) to (d) above, or symptoms from
at least two of the groups referred to as (e) to (h), should have been clearly
present for most of the time during a period of 1 month or more. Conditions
meeting such symptomatic requirements but of duration less than 1 month
(whether treated or not) should be diagnosed in the first instance as acute
schizophrenia-like psychotic disorder and are classified as schizophrenia if the
symptoms persist for longer periods.
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a. thought echo, thought insertion or withdrawal, and thought broadcasting;
b. delusions of control, influence, or passivity, clearly referred to body or
limb movements or specific thoughts, actions, or sensations; delusional
perception;
c. hallucinatory voices giving a running commentary on the patient’s
behaviour, or discussing the patient among themselves, or other types of
hallucinatory voices coming from some part of the body;
d. persistent delusions of other kinds that are culturally inappropriate and
completely impossible, such as religious or political identity, or
superhuman powers and abilities (e.g. being able to control the weather,
or being in communication with aliens from another world);
e. persistent hallucinations in any modality, when accompanied either by
fleeting or half-formed delusions without clear affective content, or by
persistent over-valued ideas, or when occurring every day for weeks or
months on end;
f. breaks or interpolations in the train of thought, resulting in incoherence or
irrelevant speech, or neologisms;
g. catatonic behaviour, such as excitement, posturing, or waxy flexibility,
negativism, mutism, and stupor;
h. “negative” symptoms such as marked apathy, paucity of speech, and
blunting or incongruity of emotional responses, usually resulting in social
withdrawal and lowering of social performance; it must be clear that these
are not due to depression or to neuroleptic medication;
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i. a significant and consistent change in the overall quality of some aspects
of personal behaviour, manifest as loss of interest, aimlessness, idleness, a
self-absorbed attitude, and social withdrawal.
EPIDEMIOLOGY OF SCHIZOPHRENIA
The available earlier prevalence study was conducted by Brugger et al (27)
in Germany showed prevalence of 2.4 in a defined population.  A community
survey by Essen-Moller et al (28) in Sweden revealed point prevalence of 6.7 per
1000 population at risk. The largest population survey in UK by Jeffrys et al (29)
and Ethiopia by Kebede et al (30) reported a prevalence of 5.1 and 7 respectively.
In India Dube and Kumar (31) took sample from the census based on
hospital and clinic records in four regions of Agra showed prevalence of 2.6 per
1000 population at risk. The majority of studies from 1930s to 2007 have
produced point prevalence I the range between 2.1 to 7 per 1000 population at
risk and life time prevalence of schizophrenia in the range between 15 and19 per
1000.  A door to door survey with the key informants was conducted by
Rajkumar et al (32) in Chennai revealed incidence of 0.41 based on ICD-9 criteria
and by Wig et al in north India revealed schizophrenia incidence of 0.38 (33) .
The major breakthrough study of incidence of schizophrenia, well known
as ‘WHO ten country study’ was conducted in Denmark, India, Ireland, Japan,
Russia, UK and USA showed a incidence ranging 0.16-0.42 per 1000 population
based on broad definition criteria and 0.02-0.14 based on narrow definition
criteria of schizophrenia(34). The WHO ten country study revealed the following
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findings regarding antipsychotics and medical co-morbidities. In India there are
an estimated 4.3 to 8.7 million people with schizophrenia
The outcome of ten country study relevant to our study is
1. Patients with schizophrenia have significantly higher than expected rates of
epilepsy, diabetes, arteriosclerosis, and ischaemic heart disease.
2. Obesity and the concomitant metabolic syndrome involving insulin resistance
are becoming increasingly common problems in schizophrenia patients.
3. Although a high incidence of diabetes in schizophrenia patients had been
described long before the introduction of neuroleptic treatment, a contributing
role for some of the second generation antipsychotic agents has not been ruled
out.
TREATMENT OF SCHIZOPHRENIA
Historically, there was no shortage of interventions to ‘treat’ insanity, and
later, schizophrenia. Most were palliative, barely effective and often barbaric. It
was only with the development of antipsychotic drugs and evolution of trial
methodology in the 1950s that a new era of care arrived. The discovery by Delay
and Denicker in 1953 that chlorpromazine was highly effective in alleviating
delusions, hallucinations, and disorganized thinking, was the seminal
breakthrough in the treatment of schizophrenia, the first agent to produce
sufficient relief of core psychotic symptoms to permit life outside of institutions
13
for many patients with schizophrenia, and even a return to a semblance of
function within normal limits.
Chlorpromazine and the other related typical antipsychotic drugs which were
introduced over the next 30 years have proven to be of immense benefit to vast
numbers of people who experience psychotic symptoms as a component of a
diverse group of neuropsychiatric and medical disorders, as well as drug-induced
psychoses. These drugs have been invaluable in providing clues to the aetiology
of schizophrenia and other forms of mental illness with psychotic features and as
tools in understanding fundamental neural processes, especially those involving
dopamine, a key neurotransmitter involved in psychosis. This class of drugs has
now been supplanted by the so-called atypical antipsychotic drugs, of which
clozapine is the prototype.
Table A: Antipsychotics and placebo response rates in schizophrenia (data from
NIHM collaborative study)
Antipsychotic Placebo %
Very much improved 16 1 15
Much improved 29 11 18
Improved 16 10 6
Slightly improved 31 31 0
Not improved 6 15
Worse 2 13
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PSYCHOPHARMACOLOGY AND NEUROSCIENCE OF
SCHIZOPHRENIA
The revolution in psychopharmacology and biological psychiatry started
by the introduction of chlorpromazine provided the first effective treatment for
schizophrenia, as well as ideas and evidence about the pathophysiology of the
illness. There is evidence for a variety of neurochemical abnormalities, ranging
from excessive to deficient concentrations of dopamine, serotonin, and
glutamate, in studies comparing patients with schizophrenia and controls (35).
DOPAMINE
The leading hypothesis for schizophrenia is based upon the
neurotransmitter dopamine. Dopaminergic neurons utilize the neurotransmitter
dopamine (DA), which is synthesized in dopaminergic nerve terminals from the
amino acid tyrosine after it is taken up into the neuron from the extracellular
space and bloodstream by a tyrosine pump, or transporter. Tyrosine is converted
into DA first by the rate-limiting enzyme tyrosine hydroxylase (TOH) and then
by the enzyme DOPA decarboxylase (DDC). DA is then taken up into synaptic
vesicles by a vesicular monoamine transporter (VMAT2) and stored there until it
is used during neurotransmission. The DA neuron has a presynaptic transporter
(reuptake pump) called DAT, which is unique for DA and which terminates
DA’s synaptic action by whisking it out of the synapse back into the presynaptic
nerve terminal; there it can be restored in synaptic vesicles for subsequent reuse
in another neurotransmission. DATs are not present in high density at the axon
terminals of all DA neurons. For example, in prefrontal cortex, DATs are
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relatively sparse and DA is inactivated by other mechanisms. Excess DA that
escapes storage in synaptic vesicles can be destroyed within the neuron by the
enzymes monoamine oxidase (MAO)-A or MAO-B, or outside the neuron by the
enzyme catechol-Omethyl- transferase (COMT). DA that diffuses away from
synapses can also be transported by norepinephrine transporters (NETs) as a
false substrate, and DA action will be terminated in this manner.
The DA transporter DAT and the vesicular transporter VMAT2 are both
types of receptors. A plethora of additional dopamine receptors exist, including
at least five pharmacological subtypes and several more molecular isoforms.
Perhaps the most extensively investigated dopamine receptor is the dopamine 2
(D2) receptor, as it is stimulated by dopamine agonists for the treatment of
Parkinson’s disease, and blocked by dopamine antagonist antipsychotics for the
treatment of schizophrenia. Dopamine 1, 2, 3, and 4 receptors are all blocked by
some atypical antipsychotic drugs, but it is not clear to what extent dopamine 1,
3, or 4 receptors contribute to the clinical properties of these drugs.
Dopamine 2 receptors can be presynaptic, where they function as autoreceptors.
Presynaptic D2 receptors thus act as gatekeepers, either allowing DA release
when they are not occupied by DA or inhibiting DA release when DA builds up
in the synapse and occupies this gate keeping presynaptic autoreceptors. Such
receptors are located either on the axon terminal or on the other end of the
neuron in the somatodendritic area. In both cases, occupancy of these D2
receptors provides negative feedback input, or a braking action upon the release
of dopamine from the presynaptic neuron.
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The early 1960s implicated monoamines in the effects of the antipsychotic drugs
and in the pathophysiology of schizophrenia and related drug side effects.
Dopamine was one of the approximately 10 neurotransmitters distributed
diffusely throughout the brain considered for pathophysiology of schizophrenia.
The strongest support for a connection between dopamine function and
schizophrenia came from studies showing that the clinical efficacy of drugs
depends on their ability to block dopamine receptors, especially the dopamine
D2 receptor subtype. These studies, carried out in the 1970s, used post-mortem
brain tissue samples. The studies of dopamine metabolites in the cerebrospinal
fluid and dopamine receptor binding that used in vivo functional neuroimaging
provided additional evidence for dopamine abnormalities in schizophrenia.
SEROTONIN
In 1943, Swiss chemist Albert Hoffman ingested a new chemical
compound—an ergot derivative called lysergic acid diethylamide (LSD). He
experienced psychotic delusions and vivid hallucinations. That experience led
him to the studies of drugs that produce psychotic symptoms. LSD seemed to
enhance and potentiate the effects of serotonin in the brain. This finding initiated
interest in the role of serotonin in schizophrenia, which was rekindled in the late
1980s and early 1990s with the development of atypical antipsychotic drugs,
starting with clozapine and risperidone. These compounds appeared to work by
blocking both dopamine D2 and serotonin 5HT2 receptors. This dual activity
distinguished these newer, atypical antipsychotics from the older, typical
antipsychotics that only blocked dopamine receptors. The serotonin-blocking
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action seemed to be an important part of the demonstrated efficacy for positive
and, to some extent, negative symptoms of schizophrenia, as well as a reduction
in the risk of tardive dyskinesia with atypical compared with typical
antispychotics. Other, newer atypical antipsychotic agents developed since then,
such as olanzapine, quetiapine, ziprasidone, and aripiprazole, share this dual
neurotransmitter action. However, direct evidence for a primary role of serotonin
in the pathophysiology of schizophrenia remains less convincing compared to
that for dopamine.
GLUTAMATE (36)
The search for other altered neurotransmitter systems involved in the
pathophysiology of schizophrenia continues. Glutamate is a principal excitatory
neurotransmitter distributed in the brain structures implicated in schizophrenia,
such as the frontal cortex, hippocampus, and entorhinal cortex. Dopamine
antagonizes the glutamate system, reducing glutamate release. The most
suggestive evidence for the role of glutamate comes from the effects of a drug of
abuse, phencyclidine (PCP), which serves as one of the putative neurochemical
models for schizophrenia (Kornhuber, 1990). PCP binds to a specific site on the
N-methyl-D-aspartate (NMDA) receptor and blocks the action of glutamate,
which is considered to be responsible for its analgesic, anesthetic, and
physiological effects. Supportive evidence comes from postmortem
neuropathological studies reporting reduction in the glutamate transmitter
binding in brains of people with schizophrenia. Deficient glutamate
18
neurotransmission may be a primary or secondary, underlying mechanism in
schizophrenia.
Other candidate neurotransmitters include aspartate, glycine, and gamma-
aminobutyric acid (GABA), collectively dominating excitatory and inhibitory
neurotransmission. Eventually, we might discover that dysregulation of several
neurotransmitter systems is the unifying underlying mechanism of the disease.
Brain imaging studies of receptor densities in young adults and children, or in
patients with first-episode schizophrenia may be helpful in identifying early
vulnerability factors.
PATHWAYS AND TARGETS (35)
Schizophrenia comprises a number of domains of disability that form useful
targets for drug treatment. These include:
 Positive symptoms
 Negative symptoms
 Cognitive symptoms
 Affective symptoms
 Disorganized and catatonic symptoms
The five dopamine pathways in the brain include the mesolimbic dopamine
pathway, the mesocortical dopamine pathway, the nigrostriatal dopamine
pathway, the tuberoinfundibular dopamine pathway, and a fifth pathway that
innervates the thalamus.
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The neuroanatomy of dopamine neuronal pathways in the brain can
explain the symptoms of schizophrenia as well as the therapeutic effects and side
effects of antipsychotic drugs.
(a) The nigrostriatal dopamine pathway, which projects from the substantia nigra
to the basal ganglia or striatum, is part of the extrapyramidal nervous system and
controls motor function and movement. Blockage of dopamine by antipsychotics
in this pathway leads to extrapyramidal side effects.
(b) The mesolimbic dopamine pathway projects from the midbrain ventral
tegmental area to the nucleus accumbens, a part of the limbic system of the brain
thought to be involved in many behaviors such as pleasurable sensations, the
powerful euphoria of drugs of abuse, as well as delusions and hallucinations of
psychosis. According to dopamine theory of schizophrenia, hyperdopaminergic
state of mesolimbic pathway causes positive symptoms.
(c) A pathway related to the mesolimbic dopamine pathway is the mesocortical
dopamine pathway. It also projects from the midbrain ventral tegmental area and
sends its axons to areas of the prefrontal cortex, where they may have a role in
mediating cognitive symptoms (dorsolateral prefrontal cortex, DLPFC) and
affective symptoms (ventromedial prefrontal cortex, VMPFC) of schizophrenia.
Hypodopaminergic state of this pathway said to be the cause for negative and
cognitive symptoms of schizophrenia.
(d) The fourth dopamine pathway of interest, the tuberoinfundibular dopamine
pathway, projects from the hypothalamus to the anterior pituitary gland and
controls prolactin secretion. Here prolactin release is under the inhibitory control
20
of dopamine. As a dopamine antagonist, antipsychotics release the inhibition of
prolactin, leads to hyperprolactinemia.
(e) The fifth dopamine pathway arises from multiple sites, including the
periaqueductal gray, ventral mesencephalon, hypothalamic nuclei, and lateral
parabrachial nucleus, and it projects to the thalamus. Its function is not currently
well known.
Picture: Dopamine pathways
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CLASSIFICATION OF ANTIPSYCHOTICS (37)
First-generation antipsychotics
I. Phenothiazines
A. Aliphatic side chain (low/medium-potency agents)
Chlorproethazine
Chlorpromazine
Cyamemazine
Levomepromazine
Promazine
Triflupromazine
B. Piperidine side chain (low/medium-potency agents)
Mesoridazine
Pericyazine
Piperacetazine
Pipotiazine
Propericiazine
Sulforidazine
Thioridazine
C. Piperazine side chain (medium/high-potency agents)
Acetophenazine
Butaperazine
Dixyrazine
Fluphenazine
22
Perazine
Perphenazine
Prochlorperazine
Thiopropazate
Thioproperazine
Trifluoperazine
II. Butyrophenones (high-potency agents)
Benperidol
Bromperidol
Droperidol
Fluanisone
Haloperidol
Melperone
Moperone
Pipamperone
Timiperone
Trifluperidol
III. Thioxanthenes (low/medium-potency agents)
Chlorprothixene
Clopenthixol
Flupenthixol
Thiothixene
Zuclopenthixol
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IV. Dihydroindolones (low/medium-potency agents)
Molindone
Oxypertine
V. Dibenzepines (low/medium-potency agents)
Clotiapine
Loxapine
VI. Diphenylbutylpiperidines (high-potency agents)
Fluspirilene
Penfluridol
Pimozide
VII. Benzamides (low-potency agents)
Nemonapride
Sulpiride
Sultopride
Tiapride
VIII. Iminodibenzyl (medium-potency agents)
Clocapramine
Mosapramine
ATYPICAL ANTIPSYCHOTICS
Dibenzodiazepine – clozapine
Dibenzothiazepine – Qutiapine
Dibenzooxipinopyrrole – Asenapine
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Dibenzothiepin – Zotepine
Thienobenzodiazepine – olanzapine
Benzisothiazolyl – ziprasidone
Benzisothiazole - Lurasidone
Benzisoxale – Risperidone, Paliperidone, Iloperidone
Substituted Benzamides – sulpiride, Amisulpiride
Quinoline – Aripiprazole
ANTIPSYCHOTIC DRUGS
Antipsychotic drugs have been classified into two broad categories:
typical and atypical (38). Typical antipsychotic drugs are those which produce
EPS at clinically effective doses, including parkinsonism (muscle rigidity,
tremor, bradykinesia), acute dystonic reactions, dyskinesias, akathisia and
tardive dyskinesia. They are also called neuroleptics because of their inhibitory
effect upon locomotion activity. They are sometimes referred to as first
generation antipsychotic drugs, but this has multiple problems as a class
designation. The prototype of the atypical class of agents is clozapine which was
first discovered during the early stages of the development of the drugs called
first generation agents. The major mode of action of typical neuroleptics is to
block dopamine D2 receptors in the limbic system, which includes the nucleus
accumbens, stria terminalis, and amygdala.
The typical antipsychotic drugs are members of a variety of chemical families.
They vary in affinity for the D2 receptor, with low affinity drugs such as
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chlorpromazine, which require high doses for clinical efficacy, to high affinity
drugs such as haloperidol, which are effective at lower doses.
Kapur and Seeman (39) have proposed that the rate of dissociation of all
antipsychotic drugs from the D2 receptor provides the basis for the distinction
between typical and atypical antipsychotic drugs, with atypical antipsychotic
drugs dissociating more rapidly. While this is true for clozapine and quetiapine,
the atypical drugs risperidone, sertindole, olanzapine and asenapine dissociate no
more rapidly or even slower than haloperidol. As such, fast dissociation cannot
provide the pharmacological basis for atypicality for most of the drugs that are
considered atypical.
Low-potency typical neuroleptic agents are those in which the usual dose
range in schizophrenia is equal to or greater than 200 mg/day, while mid- to
high-potency agents are those in which the dose range is between 2 and 175
mg/day. In general, the low-potency drugs are more sedative and more
hypotensive than the high potency agents but also have less of tendency to
produce extrapyramidal side-effects. The typical antipsychotic drugs differ from
one another with regard to potential for other side-effects, e.g. weight gain and
hypotension, but have comparable efficacy as antipsychotic agents (40).
Atypical antipsychotic drugs are those antipsychotic agents with a significantly
lower propensity to produce EPS at clinically effective doses (41). They are also
characterized by a more diverse and complex pattern of pharmacological
activity, including serotonin 5HT2A and dopamine D2 antagonism as well as a
variety of activities at other receptors whose contribution to their mode of action
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is still being elucidated (42). Substituted benzamides, e.g. amisulpride, also have
low EPS at clinically effective doses and may constitute another class of atypical
agents. New classes of atypical antipsychotic drugs are emerging from research
with considerable frequency at the current time.
The prototypical atypical antipsychotic drug is clozapine, a dibenzodiazepine (43).
Others include aripiprazole, olanzapine, quetiapine, paliperidone, risperidone,
sertindole, ziprasidone and zotepine. These drugs are all more potent 5-HT2A
than D2 receptor antagonists as well as multireceptor antagonists (44, 45) except for
aripiprazole, which is a dopamine D2 receptor partial agonist. Bifeprunox is also
a partial D2 agonist. It lacks 5-HT2A receptor blocking properties, relying
instead on 5-HT1A partial agonism to reduce serotonergic tone. Amisulpride is a
substituted benzamides.
Although the efficacies of all antipsychotics are same, they differ in
adverse effect profile. A meta-analysis of short-term trials involving patients
with schizophrenia or related disorders shown that their mean weight gain was
found higher for iloperidone, olanzapine and clozapine; intermediate for
risperidone, quetiapine and paliperidone; and lower for asenapine, lurasidone,
aripiprazole, amisulpride, and ziprasidone. These finding is applicable to other
metabolic side effects like hypercholesterolemia and diabetes mellitus too in a
similar fashion.
Antipsychotics and weight gain
Clozapine and olanzapine are the antipsychotics that cause more weight
gain. A metaanalysis carried out by Allison et al (46) has estimated mean change
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in weight secondary to antipsychotics after 10 weeks. In decreasing order:
clozapine (+3.99 kg), olanzapine (+3.51 kg), thioridazine (+3.49 kg),
chlorpromazine (+2.10 kg), risperidone (+2.0 kg) and haloperidol (+0.48).
Fluphenazine (+0.43 kg) and ziprasidone (+0.04 kg) are not associated with
statistically significant weight gain. Molindone was associated with slight weight
loss (-0.81 kg). Pimozide apparently does not cause weight gain, but data found
did not allow adequate analysis. It is worth stressing that weight gain may
continue for a much longer period than what was demonstrated in another study,
reaching up to 46 weeks in patients taking clozapine (47).
Other studies have presented similar findings. Czobor et al (48) analyzed a
double-blind trial comparing efficacy of haloperidol (n = 36), clozapine (n = 38),
olanzapine (n = 38) and risperidone (n = 39) after 14 weeks and verified that
only haloperidol did not cause significant weight gain. In that study, the authors
have found strong association between weight gain and therapeutic response to
clozapine and olanzapine, but not for haloperidol and risperidone. Simpson et al
(49) compared efficacy and tolerability of ziprasidone and olanzapine in acute
schizophrenia or schizoaffective disorder patients.
After 6 weeks, they verified significantly increased weight and body mass index
(BMI) in the olanzapine group. Finally, recent data have been presented by the
study Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) (50).
CATIE, an independent clinical trial funded by the National Institute of Mental
Health 6 (NIMH), has assessed, in its first stage, effectiveness of antipsychotics
by independently comparing four atypical antipsychotics (olanzapine,
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quetiapine, risperidone and ziprasidone) and one traditional antipsychotic
(perphenazine). In that study, the number of patients taking olanzapine who
presented weight gain higher than 7% was significantly higher than those taking
quetiapine, risperidone, perphenazine and ziprasidone (30 versus 16, 14, 12 and
7%, respectively). Mean weight gain per month of treatment was 0.2 kg for
quetiapine, 0.9 kg for olanzapine, 0.2 kg for risperidone, & -0.1 kg for
ziprasidone. Aripiprazole, which was not included in the CATIE study neither in
the meta-analysis described above, is probably not associated with significant
weight gain. McQuade et al (51) have assessed participants of a controlled double-
blind study comparing aripiprazole and olanzapine in the treatment of acute
schizophrenia. The aripiprazole group presented mean weight loss of 1.37 kg at
week 26, whereas the olanzapine group had weight gain of 4.23 kg. Fourteen per
cent of patients in the aripiprazole group presented weight gain ≥ 7% initial
weight, versus 37% of patients in the olanzapine group. Another open study with
a small number of patients has suggested that aripiprazole may reverse weight
gain in patients who have previously taken other antipsychotics (52). Weight gain
also occurs with some depot antipsychotics.
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Table B: Hypothesized therapeutic and adverse effects of receptor occupancy by
antipsychotic drugs (53)
Target receptor Pharmacological
activity
Therapeutic effect(s) Adverse effect(s)
Dopamine D2 Antagonism or
partial agonist
effects
Reduction of positive
symptoms
Extrapyramidal
effects (EPS)
Hyperprolactinemia
Serotonin (5-HT)
1A
Full or partial
agonist effects
Cognitive
enhancement
Reduction of mood
and anxiety
symptoms
5-HT 2A Antagonism Reduction of negative
symptoms
Reduction of EPS
Reduction of mood
and anxiety
symptoms
Increased deep sleep
5-HT 2C Antagonism Reduced anxiety
symptoms
Weight gain
Adrenergic α-1 Antagonism Orthostatic
hypotension
Dizziness
Adrenergic α-2 Antagonism Reflex tachycardia
Histamine H-1 Sedation Sedation
Drowsiness
Weight gain
Muscarinic
(cholinergic)M-1
Antagonism Reduction of EPS Blurry vision
Exacerbation of
acute angle closure
glaucoma
Sinus tachycardia
Constipation
Urinary retention
Memory
dysfunction
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RISPERIDONE (54)
Risperidone, a psychotropic agent belonging to the chemical class of
benzisoxazole derivative.
Molecular formula - C23H27FN4O2
Molecular weight - 410.49.
PHARMACOKINETICS
Risperidone undergoes extensive first-pass hepatic metabolism to 9-
hydroxyrisperidone, a metabolite with equivalent antipsychotic activity. Peak
plasma levels of the parent compound occur within 1 hour for the parent
compound and 3 hours for the metabolite. Risperidone has a bioactivity of 70
percent. The combined half-life of risperidone and 9-hydroxyrisperidone
averages 20 hours, so it is effective in once-daily dosing. Risperidone & its
metabolites eliminated through urine and, to a lesser extent through the faeces.
PHARMACODYNAMICS
Risperidone is an antagonist of the serotonin 5-HT2A, dopamine D2,
alpha1- and alpha2-adrenergic, and histamine H1 receptors. It has a low affinity
for alpha1-adrenergic and muscarinic cholinergic receptors. Although it is as
potent an antagonist of D2 receptors as is haloperidol, risperidone is much less
likely (except in high doses) than haloperidol to cause extrapyramidal symptoms
in humans.
METABOLISM AND INTERACTIONS
CYP 2D6 is the enzyme responsible for metabolism of many neuroleptics,
antidepressants and antiarrhythmics. CYP 2D6 undergoes genetic polymorphism
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and to inhibition by a number of substrates and also by fewer non-substrates,
notably quinidine. Extensive CYP 2D6 metabolizers convert risperidone rapidly
into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much
more slowly.
Risperidone can produce two types of drug-drug interactions. First, inhibitors of
CYP 2D6 interfere with conversion of risperidone to 9-hydroxyrisperidone. This
occurs with quinidine, giving essentially all recipients a risperidone
pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits
and adverse effects of risperidone in patients receiving quinidine have not been
evaluated, but observations in a modest number of poor metabolizers given
risperidone do not suggest important differences between poor and extensive
metabolizers. Second, co-administration of known enzyme inducers (e.g.,
carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may
cause a decrease in the combined plasma concentrations of risperidone and 9-
hydroxyrisperidone.
It would also be possible for risperidone to interfere with metabolism of other
drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the
enzyme suggests this is unlikely.
INDICATIONS
 Acute and maintenance phase of schizophrenia
 Bipolar mood disorder
 Any agitation and aggressive behaviour associated with organic
conditions, mental retardation, autism
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 Delirium
 Adjuvant in Attention deficit and hyperkinetic disorder
 Tic disorders
SIDE EFFECTS
 Extrapyramidal effects of risperidone are largely dosage dependent, and a
trend is seen to using lower doses than initially recommended.
 Weight gain, anxiety, nausea and vomiting, rhinitis, erectile dysfunction,
orgasmic dysfunction, and increased pigmentation are associated with
risperidone use.
 The most common drug-related reasons for discontinuation of risperidone
use are extrapyramidal symptoms, dizziness, hyperkinesias, somnolence,
and nausea.
 Marked elevation of prolactin can occur.
 Weight gain occurs more commonly with risperidone use in children than
in adults.
DOSAGES
The recommended dose range and frequency of risperidone dosing has
changed since the drug first came into clinical use. Risperidone is available in 1-,
2-, 3-, and 4-mg tablets, and a 1-mg/mL oral solution and in M-tab form (rapidly
dissolving). The initial dosage is usually 1 to 2 mg at night, which can then be
raised to 4 mg per day. Positron emission tomography (PET) studies have shown
that dosages of 1 to 4 mg per day provide the required D2 blockade needed for a
therapeutic effect. At first it was believed that because of its short elimination
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half-life, risperidone should be given twice a day, but studies have shown equal
efficacy with once-a-day dosing. Dosages above 6 mg a day are associated with
a higher incidence of adverse effects, particularly extrapyramidal symptoms. No
correlation has been found between plasma concentrations and therapeutic
effect.
Risperidone (Risperdal Consta) is available in a depot formulation. It is
given as an intramuscular (IM) injection formulation every 2 weeks. The dose
may be 25, 50, or 75 mg. Oral risperidone should be coadministered with
Risperdal Consta for the first 3 weeks before being discontinued.
Risperidone is a first line pharmacological treatment of schizophrenia and other
forms of psychosis. It may produce significant advantages over typical
neuroleptic drugs with regard to negative symptoms, cognition, and
extrapyramidal side-effects, but it does produce dose dependent increases in EPS
risk, and increases in serum prolactin levels resembling those of typical
antipsychotic drugs. It should be used at the lower doses where possible.
Risperidone is often initiated in twice daily dosing; however, because its primary
active metabolite, 9-OH risperidone, is pharmacologically equivalent to its
parent drug and because it has a longer elimination half-life, once daily dosing is
also possible.
Risperidone has more of a tendency to produce extrapyramidal side-
effects than any of the other atypical antipsychotics but this can be minimized by
using the lowest dose which controls positive symptoms and adding an
anticholinergic drug, if necessary. Among atypical antipsychotic drugs,
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risperidone and paliperidone appear to be the most liable in terms of increasing
prolactin release. As is the case with EPS, the effect of risperidone on prolactin
concentration appears to positively correlate with dose (55). The changes may
occur in both men and women; however, the greatest elevations appear to occur
among women. Elevations in prolactin levels as a result of treatment with
risperidone do not always translate into clinical symptoms such as sexual
dysfunction or gynaecomastia in men and menstrual changes and breast
discharge in women; however, patients should be monitored clinically for these
effects, and prolactin concentrations measured if these symptoms occur.
Risperidone is the second generation antipsychotic that gained approval
of the Food and Drug Administration in 1994 and since then is gaining rapid
popularity. There are various studies which provide evidences that risperidone is
as effective as typical antipsychotics in treating positive symptoms and more
effective in treatment of negative symptoms (55) .
In a open labelled randomized controlled study, Patients with the diagnosis of
schizophrenia were randomly assigned to receive risperidone 4-6 milligrams  per
day and haloperidol 10-20 mg per day, and were followed up for 6 weeks.
Assessment was done on the day of the diagnostic interview and days 7, 14, 28
and 42. During the assessment periods Positive and Negative Syndrome Scale
(PANSS) was administered to monitor the progress in psychopathology and
Udvalg for Kliniske Undersogelser (UKU) side effects rating scale was applied
to rate the treatment emergent adverse effects.
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Both risperidone and haloperidol were associated with substantial baseline- to-
endpoint reduction in symptom severity. Thirty-eight percent of risperidone
treated patients had to resort to anti-parkinsonian treatment compared to 78% in
haloperidol treatment group.
In one other prospective, randomized open label 6-week study, 80
patients with diagnosis of Schizophrenia were randomized to two groups to
receive either risperidone (4-8 mg) or iloperidone (6-24 mg). Their efficacy was
assessed using reduction in PANSS score and safety profile was assessed by
monitoring the adverse effects during follow-up visits at 2, 4, 6 weeks. PANSS
score showed significant reduction in both groups as compared to baseline
values after 6 weeks. But there were no significant differences between two
groups. The safety profile assessed by comparison of adverse effects showed
statistically significant differences between the groups (<0.01) (56).
In a study where comparison of risperidone with clozapine in patients
with treatment resistant schizophrenia Bondolfi et al (57) found, both risperidone
and clozapine significantly reduced the severity of psychotic symptoms from
baseline, with no significant between-group differences. At endpoint, 67% of the
risperidone group and 65% of the clozapine group were clinically improved
(reduction of 20% or more in total Positive and Negative Syndrome Scale score).
Risperidone appeared to have a faster onset of action. In both groups
extrapyramidal symptoms and other adverse events were few, and their severity
was generally mild.
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Magali Haas et al (58) studied the efficacy and safety of two risperidone
regimen, 1.5–6.0 mg/day (regimen A) or 0.15–0.6 mg/day (regimen B) in
adolescent schizophrenic patients. He found significant improvement in mean
total PANSS scores in regimen A group than regimen B group. The regimen A
group shown significant improvement in both the positive and negative symptom
scores than regimen B group. Overall, risperidone was well tolerated in these
patients.
An international, multicenter, double-blind study was conducted by R.A.
Emsley (59) in 183 patients with a first psychotic episode treated with flexible
doses of risperidone or haloperidol for 6 weeks. At endpoint, 63 percent of
risperidone-treated patients and 56 percent of haloperidol-treated patients were
clinically improved, in which 50% reduction in Positive and Negative Syndrome
Scale total scores was considered as response or improvement. Risperidone was
better tolerated than haloperidol in his study and the severity of extrapyramidal
symptoms was significantly lower in the risperidone treated patients. Because of
this significantly fewer risperidone treated patients required antiparkinsonian
medication.
In a multicenter study of comaprsion of risperidone with haloperidol in
the prevention of relapse, John g. C sernansky et al (60) estimate the risk of
relapse at the end of the study was 34 percent for the risperidone group and 60
percent for the haloperidol group. Huafang Li et al (61) compared the efficacy and
safety of blonanserin and risperidone in Chinese schizophrenia patients aged
between 18 and 65 years. Patients with Positive and Negative Syndrome Scale
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(PANSS) total scores more than 70 and less than 120 were randomized to
receive blonanserin or risperidone using a gradual dose-titration method
(blonanserin tablets: 8-24 mg/day; risperidone tablets: 2-6 mg/day), twice daily.
Treatment populations consisted of 128 blonanserin-treated patients and 133
risperidone-treated patients. Reductions of PANSS total scores by blonanserin
and risperidone treatment were 30.59 and 33.56, respectively. Risperidone
treatment was associated with elevated levels of serum prolactin (67.16%
risperidone versus 52.31% blonanserin) and cardiac-related abnormalities
(22.39% risperidone versus 12.31% blonanserin), and blonanserin patients were
more prone to extrapyramidal side effects (48.46% blonanserin versus 29.10%
risperidone).  He concluded, blonanserin was as effective as risperidone for the
treatment of Chinese patients with schizophrenia. The overall safety profiles of
these drugs are comparable, although blonanserin was associated with a higher
incidence of EPS and risperidone was associated with a higher incidence of
prolactin elevation and weight gain.
Prasanna Kumar Neredumilli (62) conducted a 12 weeks open label
prospective study of antipsychotic drugs olanzapine, risperidone and haloperidol
in patients with schizophrenia. 80 patients having diagnosis of schizophrenia
according to ICD-10 are assigned to treatment with olanzapine (N=20),
risperidone (N=20) and haloperidol (N=40). Assessment for analysis include
weight, body mass index(BMI), fasting blood glucose(FBS), postprandial blood
glucose (PPBS) at baseline and at 4th week ,8th week and 12th week. Lipid
profile is assessed at baseline and 12th week. Out of 80 subjects, only 65 patients
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completed the study; there are 15 dropouts. At the end of 12 weeks in
haloperidol group, there is a mean increase of 3.2 mg/dl in FBS and 2.71 mg/dl
PPBS and mean decrease of 2.76 mg/dl in serum cholesterol levels. In
olanzapine group there is a mean increase of 6.3 mg/dl in FBS and 3.7 mg/dl in
PPBS and mean increase of 7.8 mg/dl in serum cholesterol. In risperidone group,
there is mean increase of 2.3 mg/dl in FBS and 2.8 mg/dl in PPBS and mean
increase of 0.98 mg/dl in serum cholesterol.
A systematic search of the PubMed, EMBASE and Cochrane databases
(63) was conducted to identify studies that reported randomized controlled trials
(RCTs) comparing changes in blood glucose levels between patients receiving
one of 12 antipsychotic drugs or a placebo for the treatment of schizophrenia or
related disorders. The primary outcome of interest was changes in fasting
glucose levels. They included around 47 studies. Of the antipsychotic drugs,
only olanzapine was associated with significantly increased glucose levels
compared to a placebo. Moreover, olanzapine was associated with a significantly
greater change in the glucose levels than ziprasidone ,lurasidone or risperidone .
Ziprasidone and lurasidone were associated with minimal glucose changes
compared to the other antipsychotics
LURASIDONE (64)
Lurasidone is an atypical antipsychotic drug approved for the treatment of
bipolar depressive disorder.
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Chemical class - benzisothiazol derivatives.
Molecular formula - C28H36N4O2S·HCl.
Molecular weight - 529.14.
MECHANISM OF ACTION
It blocks D2, 5-HT2A and 5-HT7 receptors. It has partial agonistic
activity on 5-HT1A receptor but has no effect on H1 and muscarinic receptors.
As like any atypical antipsychotic drugs it blocks the dopamine receptor at
mesolimbic pathway, thus improving the positive symptoms of schizophrenia.
The negative symptoms are improved by dopamine release at mesocortical
pathway which is mediated through 5HT2A antagonism.
PHARMACOKINETICS
The pharmacokinetics is dose-proportional within a total daily dose range
of 20 mg to 160 mg. Steady-state concentrations achieved within 7 days of
initiating the drug. Mean elimination half-life is 18 hours. It is absorbed and
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reaches peak serum concentrations in approximately 1-3 hours. It is estimated
that 9-19% of an administered dose is absorbed. It is highly bound (~99%) to
serum proteins. Its exposure was not affected as meal size was increased from
350 to 1000 calories and was independent of meal fat content. It is metabolized
mainly via CYP3A4. Major biotransformation pathways are oxidative N-
dealkylation, hydroxylation of norbornane ring, and S-oxidation. Lurasidone is
metabolized into two active metabolites and two major non-active metabolites.
DRUG INTERACTIONS
As it is predominantly metabolized by CYP3A4, should not be used
concomitantly with strong CYP3A4 inhibitors or strong CYP3A4 inducers. Its
dose should be reduced to half of the original level when used concomitantly
with moderate inhibitors of CYP3A4. If it is used concomitantly with a moderate
CYP3A4 inducer, it may be necessary to increase the lurasidone dose. Grapefruit
and grapefruit juice should be avoided in patients taking lurasidone.
USE IN SPECIFIC POPULATIONS
Pregnancy:  Category B Risk
ADVERSE DRUG REACTIONS
 Increased Mortality in Elderly Patients with Dementia-Related
Psychosis,
 Suicidal Thoughts and Behaviors
 Neuroleptic Malignant Syndrome
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 Tardive Dyskinesia
 Metabolic Changes (Hyperglycemia and Diabetes Mellitus,
Dyslipidemia, and Weight Gain)
 Hyperprolactinemia
 Leukopenia, Neutropenia, and Agranulocytosis
 Orthostatic Hypotension and Syncope
 Seizures
 Potential for Cognitive and Motor Impairment
 Body Temperature Dysregulation
 Suicide
 Activation of Mania/Hypomania
 Dysphagia
 Neurological Adverse Reactions in Patients with Parkinson’s
Disease or Dementia with Lewy Bodies.
Rajiv Tandon et al study about acute exacerbation of schizophrenia was to
estimate the relapse rate of each group after withdrawal of respective
intervention. He found that mean Positive and Negative Syndrome Scale total
score decreased in lurasidone group and reduction in risk of relapse. He
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concluded lurasidone is an ideal drug for maintenance phase of schizophrenia
treatment too.
With the objective to explore the cognitive and functional performance of
patients whose final doses of lurasidone were 40/80 mg/d, 120 mg/d, and 160
mg/d compared to quetiapine XR 200-800 mg/d (QXR) during a 6-month,
Philip D. Harvey et al (65) conducted a post-hoc analysis in schizophrenia
patients. He concluded that subjects who received final doses of lurasidone 120
mg/d and 160 mg/d showed significantly greater improvement in overall
cognitive performance compared to Qutiapine 600 mg XR at week 32, while
those on last doses of 40/80 mg/d showed a trend towards significance at
week 32.
Citrome et al (66) compared lurasidone with risperidone. He found most
frequent adverse effects in the lurasidone group were nausea, insomnia and
sedation and in the risperidone group were increased weight, somnolence and
headache.
Herbert Y. Meltzer et al (67) compared the efficacy of Lurasidone 40mg
and 120mg with olanzapine 15 mg to assess the short term efficacy in
schizophrenic patients. Significant improvement seen at week 6 on PANSS total
score, PANSS positive and negative subscale scores, and CGI-S score in both
dose lurasidone group or olanzapine group compared with placebo. There was
no statistically significant difference in mean PANSS total or CGI-S change
scores for the lurasidone groups compared with the olanzapine group.
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In a pharma sponsored study by Mitsutaka Nakamura et al (68) regarding
safety and efficacy of Lurasidone (80 mg/day) demonstrated a statistically
significant reduction in BPRSd score at Week 6 compared with placebo. Similar
statistically significant greater reductions in PANSS total score and CGI-S score
at Week 6 compared with placebo was found with lurasidone. In the lurasidone
and placebo groups, discontinuation rates due to adverse events were 6.7% and
1.1%, respectively. There was no statistically significant changes in weight,
lipids, and glucose were observed during treatment with lurasidone found as
compared with placebo.
In a placebo-controlled study (69) among children and adolescents with
bipolar I depression, lurasidone significantly decreased depressive symptoms in
children and adolescents with bipolar depression. Melissa P. DelBello et al found
Lurasidone was well tolerated, with minimal effects on weight and metabolic
parameters in children and adolescents.
In an attempt to study the safety and efficacy of lurasidone in
schizophrenic patients Masaaki Ogasa et al (70) compared 40mg and 120 mg
fixed doses with placebo and found that the mean change in BPRS score was
significantly greater in patients receiving lurasidone 40 and 120 mg/day versus
placebo.  In his study treatment with lurasidone 120 mg/day was superior to
placebo across all secondary measures, including PANSS total, PANSS positive,
PANSS negative, and PANSS general psychopathology subscales and Clinical
Global Impression of Severity. Treatment with lurasidone 40 mg/day was
superior to placebo on the PANSS positive subscale. The most common adverse
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events for patients receiving lurasidone were nausea (16.2 versus 4.0 % for
placebo) and sedation (16.2 versus 10.0 % for placebo). Minimal changes in
weight, cholesterol, triglyceride, and glucose levels indicate less metabolic
adverse profile of this drug.
Lurasidone (80 and 160mg) was compared with qutiapine 600XR and
placebo by Antony Loebel et al (71) in schizophrenic patients for 6 weeks short
term trial. He found both lurasidone and quetiapine shown significant
improvement at Week 6 on PANSS score and CGI-S score compared with
placebo. Endpoint changes in levels of cholesterol, triglycerides, and low-density
lipoprotein (LDL) cholesterol were comparable for both lurasidone groups and
placebo.
Short-term safety profile of lurasidone in phase II and phase III trials with
placebo and active comparators like haloperidol, ziprasidone, risperidone,
quetiapine, and olanzapine (72). The most common adverse drug reactions
reported were akathisia, nausea, sedation, somnolence, parkinsonism, insomnia,
agitation, anxiety, and dystonia. Apparent dose-related adverse drug reactions
were akathisia and somnolence. Other common adverse events were not dose-
related (73).
Short-term clinical trials of lurasidone shown EPS, akathisia, and dystonia
were more reported more than in placebo group. However, the mean changes
from baseline were similar for EPS and dyskinesias (74).
Lurasidone was not significantly related with movement disorders and extra
pyramidal symptoms was seen at the maximum dose of lurasidone (120
45
mg/day). In a long-term study with risperidone as active comparator, akathisia
occurred in 14.3% of lurasidone group and 7.9% of risperidone group (75).
Mean changes in QTc were similar for lurasidone, olanzapine and
placebo. Women were reported fewer in both studies because gender is a
significant risk factor for QTc prolongation and torsades des pointes. (76)
No significant metabolic effects were reported for lurasidone. In studies
with an active comparator, changes in glucose were similar for lurasidone and
ziprasidone (+4.7 and +4.8 mg/dL, respectively); glucose was also unchanged in
lurasidone and placebo treated patients (+1.0 mg/dL) but higher in olanzapine
and haloperidol-treated patients (+4.0 mg/dL and +2.0 mg/dL, respectively).
Long-term comparison studies with risperidone, lurasidone lowered glucose by
0.5 mg/dL from baseline, while risperidone raised it by 3.0 mg/dl. (70) No
increases were reported in total cholesterol, low-density lipoprotein cholesterol,
or triglycerides in short-term trials comparing lurasidone with placebo.
Short-term controlled studies, lurasidone had shown reduction in
triglycerides (−2.6 mg/dl) while ziprasidone was associated with an increase
(+22.4 mg/dL), but no difference was reported for mean change in total
cholesterol (−6.4 and −4.4 mg/dL, respectively).
Long-term studies with risperidone, the median reduction from baseline
for lipid variables was similar in lurasidone and risperidone groups (77).
Lurasidone can raise prolactin levels, with a dose-dependent relationship
in short-term clinical trials. Hyperprolactinemia was slightly greater in female
patients. In the pooled analysis of short-term placebo-controlled trials, the mean
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change in prolactin levels from baseline was significantly different from
placebo: +1.1 ng/mL for lurasidone-treated patients (0. 3 ng/mL for 40 mg and
3.4 ng/ml for 120 mg) and −0.6 ng/mL for placebo-treated patients. Mean
changes in prolactin levels were greater in patients treated with haloperidol (+8.5
ng/mL), than with olanzapine, lurasidone, and placebo (+3.7 ng/mL, +1.1
ng/mL, and −0.5 ng/mL, respectively). The increase in prolactin level for
lurasidone 120 mg/day (+10.9 ng/mL) was significantly greater than with
olanzapine (+5.0 ng/ml) or placebo (−2.5 ng/ml).
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AIM OF THE STUDY
To evaluate the efficacy and safety of lurasidone versus risperidone in
schizophrenia patients.
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METHODOLOGY
STUDY TYPE:
Interventional clinical study
STUDY DESIGN:
Randomised, Open label, prospective, comparative, clinical study
SAMPLE SIZE:
Total of 50 patients (25 patients in each group).
STUDY DURATION:
From May 2017 to April 2018(12 months)
STUDY DRUG AND DOSAGE:
Lurasidone, starting dose 40 mg/day titrated up to 80 mg /day.
STUDY PLACE:
Department of Psychiatry, Tirunelveli Medical College Hospital, Tirunelveli
INCLUSION CRITERIA:
 Patients aged between 18 to 60yrs.
 Patients with new onset of symptoms  who fulfil the ICD-10 criteria for a
primary diagnosis of schizophrenia
 Patients having a total PANSS score of ≥80 including a score ≥4
(moderate) on two or more of positive subscale at baseline
 Patients with acute exacerbation of schizophrenia who remained drug free
for at least last 6 months also included.
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EXCLUSION CRITERIA:
 Pregnancy / Lactation
 Patients with  comorbid  conditions like neurological, metabolic
(including type I diabetes),  pulmonary, cardiovascular, gastrointestinal
and/or urological disorder
 Patients with history of liver and renal disease
 Patients with  history of gastrointestinal surgery
 Patients with history of neuroleptic malignant syndrome and  active
seizure disorder
 Patients with evidence of tardive dyskinesia, dystonia or any other
movement disorder.
 Patients with history of alcohol dependence.
WITHDRAWAL CRITERIA:
 Patients who develop severe extra pyramidal symptoms.
 Neuroleptic malignant syndrome.
 Severe drug intolerance.
 Patients requiring electro convulsive therapy for symptom control.
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ETHICAL CONSIDERATIONS:
The study was commenced after getting approval from the Institutional
Ethics Committee. Written informed consent was obtained from all the patients
included in this study, in their own vernacular language.
SCHEDULE OF STUDY VISIT
a) Screening and recruitment:
Patients who fulfil the inclusion criteria were enrolled for the study.
Demographic data of the patients were collected. Baseline investigations like
BP, complete blood count, lipid profile, blood sugar, renal function test and liver
function test were done. Severity of schizophrenia at baseline was assessed using
positive and negative symptoms scale (PANSS). Patients were randomized by
using computer generated random table in 1: 1 ratio as group A and group B,
with 25 patients in each group.
b) Treatment protocol:
Group A:
Patients were given T. Lurasidone 40 mg/ day after night meal for 6
days followed by dose titration to a maximum of 80 mg/ day.
Group B:
Patients were given T. Risperidone 4 mg/day after night meal for 3 days
followed by dose titration to a maximum of 6 mg/ day.
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FOLLOW UP:
The efficacy of group A and group B was analysed by applying rating
scale Positive and negative syndrome scale (PANSS) at the end of 4 and 6
weeks. Adverse drug reactions were recorded and monitored by interviewing
with patients, by physical examination and also by necessary lab investigations
at the end of 6 weeks. Patients were insisted to maintain a diary to note any new
occurrence of adverse drug reactions in between the follow up period. Suspected
adverse drug reactions were documented in predesigned reporting form.
EFFICACY PARAMERTERS:
PRIMARY ENDPOINT:
 Mean change from baseline to Week 6 in PANSS total scores.
SECONDARY ENDPOINTS:
 Proportion of responders (defined as 20% or greater improvement in
PANSS total score from baseline at Week 4).
 Mean change from baseline to Week 4 and 6 in PANSS positive subscale.
 Mean change from baseline to Week 4 and 6 in PANSS negative
subscale.
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Positive and Negative Syndrome Scale (PANSS)
It is widely used in the study of antipsychotic therapy.
To assess a patient using PANSS, an approximately 45-minute clinical
interview was conducted. The patient was rated from 1 to 7 on 30 different
symptoms based on the interview as well as reports of family members. Of the
30 items included in the PANSS, 7 constitute a Positive Scale, 7 a Negative
Scale, and the remaining 16 a General Psychopathology Scale. The scores for
these scales were arrived at by summation of ratings across component items.
STATISTICAL ANALYSIS:
Statistical analysis was performed by standard statistical protocol using
SPSS VERSION 21.0.
 Baseline characteristics of both the groups were tabulated by
descriptive statistics (mean, standard deviation) and frequency
table. The data obtained was coded and entered into Micro soft
Excel Worksheet (Annexure).
 The categorical data was expressed as rates, ratios and proportions.
Comparison was done using chi- square test.
 The continuous data was expressed as mean ± standard deviation
(SD) and comparison was done using independent sample ‘t’test,
ANOVA.
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 A probability (‘p’ value) of less than or equal to 0.05 was
considered as statistically significant.
PATIENT DISPOSITION: CONSORT DIAGRAM
Screened (n = 62)
Completed study n=25
Group A (n= 25 )
T.Lurasidone 40 – 80 mg for 6
weeks
Group B (  n = 25 )
T.Risperidone 4 - 6 mg for 6 weeks
Randomization
Enrolled (n = 50)
Completed study n=25
54
RESULTS
Based on the inclusion and exclusion criteria totally 62 patients were
screened. Out of which 12 patients did not meet the eligibility criteria and 2 were
not willing to participate in the study were excluded. 50 patients were enrolled
for the study. They were randomly assigned in to 2 groups to receive lurasidone
and risperidone through a computer generated random table. All the patients
completed the study and the results were analysed.
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TABLE1: BASELINE PATIENT CHARACTERISTICS
BASELINE
CHARACTERISTICS
LURASIDONE
n (%)
RISPERIDONE
n (%)
TOTAL
n= 50
p
VALUE
AGE (in years)
16-25
26-35
36-45
46-60
2(50%)
6(32%)
12(60%)
5(71%)
2(50%)
13(68%)
8(40%)
2(29%)
4
19
20
7
0.198
SEX
Male
Female
15(55%)
10(43%)
12(45%)
13(57%)
27
23 0.395
LOCALITY
Rural
Urban
20(50%)
5(50%)
20(50%)
5(50%)
40
10 1.000
MARITAL STATUS
Married
Unmarried
18(52%)
7(46%)
17(48%)
8(54%)
35
15 0.758
DURATION OF
ILLNESS
< 4 months
4-6 months
7-12 months
>  1 year
5(45%)
3(60%)
7(46%)
10(53%)
6(55%)
2(40%)
8(54%)
9(47%)
11
5
15
19 0.938
FAMILY HISTORY
Yes
No
11(52%)
14(49%)
10(48%)
15(51%)
21
29 0.774
SUICIDE ATTEMPT
Yes
No
9(56%)
16(47%)
7(44%)
18(53%)
16
34 0.544
p value statistically insignificant.
Table 1: Shows comparison of baseline characteristics in  lurasidone and
risperidone groups. There were no significant difference in baseline
characteristics between the two groups.
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FIGURE 1
PANSS POSITIVE SCALE FOR LURASIDONE
Figure 1 shows significant reduction in positive scale in 4 and 6 weeks in
lurasidone group.
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FIGURE 2
PANSS POSITIVE SCALE FOR RISPERIDONE
Figure 2 shows significant reduction in negative scale in 4 and 6 weeks in
risperidone goup.
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TABLE 2
COMPARISON OF PANSS POSITIVE SCALE IN BOTH GROUPS
POSITIVE SCALE
LURASIDONE
(MEAN±SD)
RISPERIDONE
(MEAN±SD)
p VALUE
BASELINE 33.48 ± 7.5 34.00 ± 7.2 0.805
WEEK 4 22.36 ± 6.2 22.00 ± 6.2 0.839
WEEK 6 16.04 ± 6.2 14.00 ± 9.9 0.206
Table 2: Shows reduction of PANSS positive scale in both lurasidone and
risperidone groups from baseline to week 4 and 6. The difference between two
groups was statistically insignificant. (p<0.05 is significant)
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FIGURE 3
PANSS NEGATIVE SCALE-LURASIDONE
Figure 3 shows significant reduction in PANSS negative scale in 4 and 6 weeks
in lurasidone group.
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FIGURE 4
PANSS NEGATIVE SCALE RISPERIDONE
Figure 4: Shows significant reduction in PANSS negative scale in 4 and 6
weeks in risperidone group.
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TABLE 3
COMPARISON OF PANSS NEGATIVE SCALE IN BOTH GROUPS
NEGATIVE SCALE
LURASIDONE
(MEAN±SD)
RISPERIDONE
(MEAN±SD)
P VAVUE
BASELINE 29.44 ± 6.52 28.92 ± 7.83 0.798
WEEK 4 20.08 ± 5.2 18.16 ± 6.16 0.241
WEEK 6 14.52 ± 5.5 13.04 ± 4.71 0.315
Table 3: Shows reduction of PANSS negative scale in both lurasidone and
risperidone groups from baseline to week 4 and 6. The difference between two
groups was statistically insignificant.
62
TABLE 4
PANSS TOTAL SCORE - LURASIDONE
PANSS TOTAL SCORE MEAN SD P VALUE
BASELINE
114.28 17.1 0.001
WEEK 4 72.2 18.8 0.001
WEEK 6 51.6 18.4 0.001
Table 4 Shows significant reduction of PANSS total score in lurasidone  group
from baseline to week 4 and 6.
63
FIGURE 5
PANSS TOTAL SCORE - LURASIDONE
Figure 5: Shows significant reduction of PANSS total score in lurasidone group
from baseline to week 4 and 6.
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TABLE 5: PANSS TOTAL SCORE - RISPERIDONE
PANSS TOTAL SCORE MEAN SD P VALUE
BASELINE 105.96 11.8 0.001
WEEK 4 66.12 20.34 0.001
WEEK 6 46.96 14.57 0.001
Table 5 Shows significant reduction of PANSS total score in risperidone group
from baseline to week 4 and 6.
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FIGURE 6
PANSS TOTAL SCORE - RISPERIDONE
Figure 6: Shows significant reduction of PANSS total score in risperidone group
from baseline to week 4 and 6.
66
TABLE 6
COMPARISON OF PANSS TOTAL SCORE IN BOTH GROUPS
PANSS TOTAL SCORE
LURASIDONE
(MEAN ± SD)
RISPERIDONE
(MEAN ± SD)
P VALUE
BASELINE 114.28 ± 17.1 105.96 ± 11.8 0.051
WEEK 4 72.20 ± 18.8 66.12 ± 20.34 0.279
WEEK 6 51.6 ± 18.4 46.96 ± 14.57 0.321
Table 6: Shows reduction of PANSS total score in both lurasidone and
risperidone groups from baseline to week 4 and 6. The difference between two
groups was statistically insignificant.
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FIGURE 7
COMPARISON OF PANSS TOTAL SCORE IN BOTH GROUPS
Figure 7: Shows reduction of PANSS total score in both lurasidone and
risperidone groups from baseline to week 4 and 6. The difference between two
groups was statistically insignificant.
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TABLE 7 PROPORTION OF RESPONDERS TO TREATMENT
BETWEEN GROUPS
RESPONDERS TO TREATMENT -IMPROVEMENT IN PANSS SCORE
IMPROVEMENT LURASIDONE RISPERIDONE TOTAL
RESPONDERS 22 20 42
NON RESPONDERS 3 5 8
P VALUE - 0.440
CHI SQUARE TEST
NON SIGNIFICANT
Table 7 Difference in proportion of responders to treatment between two groups
was statistically insignificant.
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FIGURE 8 PROPORTION OF RESPONDERS TO TREATMENT
BETWEEN GROUPS
Figure 8: Difference in proportion of responders to treatment between two
groups was statistically insignificant.
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TABLE 8: COMPARISON OF BASELINE METABOLIC PARAMETERS
IN BOTH GROUPS
TABLE 8.1
WEIGHT &BMI
PARAMETERS
LURASIDONE RISPERIDONE
Baseline 6 weeks p
value
Baseline 6weeks p
value
WEIGHT 58±14.4 59.44±14.17 0.002 62.44±13.52 64.52±13.57 0.001
BMI 21.85±4.61 21.85±4.68 0.001 23.01±4.85 23.81±4.81 0.001
Table 8.1 Statistically significant increase in weight gain and BMI were seen in
both the groups from baseline to week 6.
.
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TABLE 8.2
BLOOD PRESSURE
PARAMETERS
LURASIDONE RISPERIDONE
Baseline 6weeks p
value
Baseline 6weeks p
value
SBP 119.12±11.4 121.84±14.52 122.88±15.
9
125.92±14.
72
DBP 77.30±11.25 79.44±9.84 80.64±8.48 81.44±7.84
Table 8.2 shows no significant difference in SBP and DBP in both the groups at
baseline and week 6.
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TABLE 8.3
BLOOD SUGAR
PARAMETERS
LURASIDONE RISPERIDONE
Baseline 6weeks p
value
Baseline 6 weeks p
value
FBS 102.68±20.14 107.6±25.1 0.136 97.52±18.51 104.52±17.87 0.013
PPBS 135.60±31.49 140.24±30.12 0.267 143.48±45.01 150.12±44.57 0.036
Table8.3 Statistically significant increase in FBS and PPBS was seen only
in risperidone group not in lurasidone group.
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TABLE 8.4
LIPID PARAMETERS
PARAMETERS LURASIDONE RISPERIDONE
Baseline 6weeks p
value
Baseline 6 weeks p
value
Total Cholesterol 156.8±28.4 164.08±29.63 0.148 155.8±28.99 169.76±30.85 0.001
Triglycerides 134.72±44.7 142.08±43.8 0.062 133±36.72 143.64±37.44 0.006
HDL 41.76±6.03 40.68±5.22 0.098 39.82±3.72 38.28±3.72 0.041
LDL 66.48±25.36 65.88±23.89 0.740 87.48±16.4 86.28±20.95 0.711
VLDL 35.65±11.41 38.16±11.48 0.060 38.16±11.48 34.76±17.42 0.140
Table 8.4 shows statistically significant increase in total cholesterol, triglycerides
and significant decrease in HDL level in risperidone group, not  in lurasidone
group.
74
TABLE 9
INCIDENCE OF DIFFERENT ADR IN BOTH GROUPS
ADR
LURASIDONE
(n)
RISPERIDONE
(n)
TOTAL
(n)
AKATHISIA 1 3 4
INSOMNIA 1 0 1
AMENORRHOEA 0 3 3
WEIGHT GAIN 6 10 10
DIABETES 0 3 3
HYPERCHOLESTEROLEMIA 2 4 6
HYPERTENSION 0 1 1
NAUSEA/VOMITING 2 2 4
DRY MOUTH 0 2 2
ERECTILE DYSFUNCTION 1 0 1
RIGIDITY 1 2 3
TREMOR 4 8 12
SEDATION 3 5 8
CONSTIPATION 0 1 1
DYSTONIA 0 1 1
Table 9 shows ADR profile in both groups.
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DISCUSSION
A total of 50 patients were enrolled in this study. Out of 50 patients 25
were included in lurasidone group and 25 were included in risperidone group. In
our study 39 patients were in the 26 – 45 years age group. The higher prevalence
of schizophrenia in this age group might be linked to stress factors as shown in
study done by Castle et al (78).
The differences in age distribution of patients between both the groups
were statistically insignificant. Analysing the gender distribution among the 50
patients who completed the study it was found that, 27 were males (15 in
lurasidone group and 12 in risperidone group) and 23 were females (10 in
lurasidone group and 13 in risperidone group). There was no gender difference
in this study which was in contradiction to  the results of recent meta-analysis
and systematic reviews which suggest that males were at higher risk for
schizophrenia compared to females.(79,80) Though the specific reason for this was
unknown, there is a possibility that schizophrenia may go unrecognized to a
larger extent in women than in men and course of the illness tends to be more
severe in men than in women that contribute to  higher prevalence in males(81).
Women tend to have a late onset which is presumed to be due to the effects of
oestrogen on reduced sensitivity of D2 receptors in the central nervous system
(82).
On analysing the impact of locality, rural patients (n=40) had more prevalence
compared to urban patients (n=10) in both the groups. In contrast to this, a
survey done by FU L et al  had shown  higher prevalence in urban areas than in
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rural areas(83).   As our hospital is a tertiary care centre most of the rural
population diagnosed with schizophrenia will be referred to government
hospital. This may be the reason for higher prevalence in rural population.
On analysing the marital status of our patients nearly 70% of them (18 in
lurasidone and 17 in risperidone) were married and 30% were unmarried. This is
in contrast with Li XJ et al study conducted in China (84).
Family history of schizophrenia was present in 21 patients in our study
population. This is similar to study done by CarstenBøcker Pedersen et al
among schizophrenia patients (85).  History of suicidal attempt was present in 16
patients in our study group. Studies so far done had not come to an agreement
on suicide rates amongst patients with schizophrenia. The most widely cited
lifetime suicide rate is 10%, as estimated by a review by Miles (86).
PANSS score was used to analyse the efficacy of the drugs in lurasidone
and risperidone group. In PANSS positive scale both groups had significant
decrease in PANSS score both at week 4 and week 6 (p<0.05). This was similar
to the results obtained in study done by Liebermmenn. The improvement in
positive symptoms in both groups is due to D2 receptor blockade along with
other dopaminergic receptors like D1, D3, D4( 87) . There was no significant
difference seen in PANSS positive scale between lurasidone and risperidone.
Similarly negative PANSS scale showed significant decrease in PANSS
score both at week 4 and week 6 in both the groups (p<0.05).  The difference
from baseline score to week 4, baseline to week 6, analysed by using student t
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test, yielded  statistically significant reduction in PANSS score in both
lurasidone and risperidone groups. There was no significant difference seen in
PANSS negative scale between lurasidone and risperidone. The improvement in
negative and cognitive symptoms in both the groups are due to blockade of
5HT2 receptors and increase in dopamine release in the prefrontal cortex by
these drugs(88). Only a few current treatment modalities had shown efficacy in
this domain (89). In recent years, several novel strategies have been evaluated (90),
including glutamatergic receptors with glycine transporter inhibitors (e.g.,
bitopertin (91) and metabotropic M2/M3 agonists (e.g., pomeglumetadmethionil)
(92). These studies have yielded positive results, which have not yet been
confirmed in subsequent studies. In addition to agents targeting the
glutamatergic system, treatments targeting nicotinic and muscarinic cholinergic
agents (93) have also emerged in recent years to treat negative symptoms of
schizophrenia.
Lurasidone had efficacy equivalent to that of the risperidone in reducing
both positive and negative symptoms (94). Patients who had more than 20 %
reduction in PANSS scale after four weeks of treatment were considered as
responders to treatment. On comparing, lurasidone had an efficacy rate of 88%
which was slightly more than that of risperidone (80%), but not statistically
significant (P>0.05).
On analysing the changes in metabolic parameters at baseline and  week 6
in both the groups, there was significant increase in (p< 0.05)  weight and body
mass index (BMI) in both lurasidone and risperidone groups. A similar study
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done by Gupta et al, (95) reported that patients undergoing treatment with
olanzapine  were  prone to develop  metabolic syndrome as the drug induces
weight gain after 16 weeks of treatment. But in our study, there was a significant
weight gain at 4 weeks of treatment itself. The molecular mechanisms
responsible for drug-induced weight gain have been hypothesized to be due to
increase in leptin secretion(96) and interactions of antipsychotic drugs with
several neurotransmitter receptors, including 5-HT(2A) and 5-HT(2C) serotonin
receptors, H(1)-histamine receptors, alpha(1)- and alpha(2)-adrenergic receptors,
and m3-muscarinic receptors. Genetic association  and polymorphism in the
resistin gene can also contribute to weight gain in these patients(97).
On analysing fasting and postprandial blood sugar levels from baseline to
week 6 in both lurasidone and risperidone groups  there was statistically
significant (p<0.05) increase only in  risperidone group but  not in lurasidone
group. Antipsychotic drugs may affect glucose transporter function. Structure-
function relationship in which similar drugs that achieve relatively higher
intracellular concentrations may similarly bind to and interfere with the function
of glucose transporter proteins. This affinity for glucose transporters can be
hypothesized to underlie clinical observations of decreased sensitivity to insulin
action. Ardizzona et al study suggest that the drugs may block glucose
accumulation directly at the level of the glucose transporter (GLUT) protein in
cells derived from both peripheral and brain tissue (98).
On analysing the lipid parameters statistically significant increase in total
cholesterol,triglycerides and significant decrease in HDL level seen in
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risperidone group only, not in lurasiodone group.. Lauressergues et al reported
that the SGAs like clozapine and olanzapine (99) as well as risperidone (100)
increased cholesterol biosynthesis in primary cultures of rat hepatocytes,
whereas other antipsychotics, such as haloperidol, quetiapine, and aripiprazole,
did not affect this pathway .In contrast to other parameters, low density
lipoprotein changes were not significant in both groups and no difference
between baseline values and at week 6. Analysis of SGOT and SGPT levels
didn’t show any significant difference after treatment for six weeks in both
lurasidone and risperidone groups.
In our study around 76% of patients had some type of adverse reaction. There
was no significant difference in incidence of adverse drug reaction between
groups , but there was difference in type of adverse reaction between groups.
The most frequent adverse effects caused by risperidone were weight gain
(n=10) followed by tremors (n=8), sedation (n=5), amenorrhea and akathisia.
The incidence of extrapyramidal side effects were higher in the risperidone
group. Metabolic derangements like diabetes and dyslipidemia were also higher
in risperidone group. Similarly, weight gain, tremors and sedation are the most
frequently reported adverse effects in lurasidone group. This was similar to the
study conducted by Peter JW et al which showed that the most common adverse
effect in risperidone group were extrapyramidal disorder, akathesia, tremor and
somnolence (101). Weight gain was seen in both the groups, but risperidone group
had shown higher mean weight gain than lurasidone. However, when significant
weight gain was considered (defined as an increase in at least 7% of body weight
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from baseline), 10 patients  in risperidone group in contrast with 6 in lurasidone
group showed significant weight gain. The study done by Peter JW et al also
showed that risperidone produced statistically significant weight gain with mean
increase of 1.5 kg (101) . The above results were similar to Dainippon long-term
phase 3 safety trial for lurasidone (102,103).
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CONCLUSION
To conclude, based on the results, lurasidone is as equally efficacious as
risperidone in reducing PANSS score, but produces less metabolic syndrome and
other adverse effects than risperidone.
APPENDIX –I
INFORMED CONSENT FORM
Study Title:
A RANDOMIZED, PROSPECTIVE COMPARATIVE STUDY TO EVALUATE
THE EFFICACY AND SAFETY OF LURASIDONE AND RISPERIDONE IN
TREATMENT OF SCHIZOPHRENIA
Study Number _______________
Subject's Full Name ___________
Date of Birth/Age___________
Address _________________
1. I confirm that I have read and understood the information sheet dated for the above study and have
hadthe opportunity to ask questions.OR I have been explained the nature of the study by the
Investigator and had the opportunity toask questions
2. I understand that my participation in the study is voluntary and that I am free to withdraw at
anytime, without giving any reason and without my medical care or legal rights being affected.
3. I understand that the sponsor of the clinical trial/project, others working on the Sponsor's behalf,the
Ethics Committee and the regulatory authorities will not need my permission to look at myhealth
records both in respect of the current study and any further research that may be conductedin relation
to it, even if I withdraw from the trial. However, I understand that my Identity will notbe revealed in
any information released to third parties or published.
4. I agree not to restrict the use of any data or results that arise from this study provided such a use
isonly for scientific purpose(s)
5. I agree to take part in the above study
Signature (or Thumb impression) of the Subject/Legal Representative: ____________________
Signatory's Name _______________________Date __________________________
Signature of the Investigator ______________ Date __________________________
Study Investigator's Name ________________Date __________________________
Signature of the Witness _________________Date __________________________
Name of the Witness
ம வ ஆ வ ப ேக க ேநாயாளக கானஅறிவ ம
ஒ த ப வ
ஆ வ தைல :
மன சிைத ேநா உ ளவ க ரசிெடா ம
ெப ேடா மா திைரகைள ெகா பதா ஏ ப ேன ற
ம ப கவைள கைள ப றிய ஒ ப ஆ .
ப ெப பவ ெபய :
ப ெப பவ வய :
1. நா ேமேல றி ப ள ம வ ஆ வ வவர கைள ப
ெகா ேட . எ ைடய ச ேதக கைள ேக க அத கான
த த வள க கைள ெபற வா பள க ப ள என
அறி ெகா ேட .
2. நா இ வா வ த ன ைசயாக ம ேம ப ேக கிேற . எ த
காரண தினாேலா, எ த க ட தி , எ த ச ட சி க
உ படாம நா இ வா வலி வலகி ெகா ளலா எ
அறி ெகா ேட .
3. இ த ஆ ச ப தமாகேவா, இைத சா ேம ஆ
ேம ெகா ேபா இ த ஆ வ ப ெப ம வ
எ ைடய ம வ அறி ைகைய பா பத எ ைடய அ மதி
ேதைவய ைல என அறி ெகா கிேற . நா ஆ வலி
வலகி ெகா டா இ ெபா என அறிகிேற .
4. இ த ஆ வ ல கிைட தகவைலேயா, ைவேயா
பய ப தி ெகா ள ம கமா ேட .
5. இ த ஆ வ ப ெகா ள மனேதா ஒ ெகா கிேற .
என ெகா க ப ட அறி ைரகள ப நட ெகா வ ட
ஆ ைவ ேம ெகா ம வ அண உ ைம ட இ ேப
என உ தியள கிேற . எ உட நல பாதி க ப டாேலா அ ல
எதி பாராத வழ க தி மாறான ேநா றி ெத ப டாேலா உடேன
இைத ம வ அணயட ெத வ ேப என உ தியள கிேற .
ப ேக பவ ைகெயா ப /ேரைக...................................................................................
இட ....................................................................... ேததி..................................................
ப ேக பவ ெபய ம
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APPENDIX – II
PANSS SCALE
0= Absent 1= Minimal   2= Mild  3= Moderate  4= Moderate Severe 5= severe
6= Extreme


APPENDIX – III
Study Proforma for GROUP-A / GROUP-B
General details
Name:
IP/OP No :
Mobile No:
Age: 16 – 25 years/ 26-35 / 36-45 / 46 -60
Sex: Male / Female
Locality: Rural / urban
Marital status: Married / Unmarried / separated or widowed
Duration of illness: < 1 month / 1-3 months /4-6 months/ >6 months
Family history of schizophrenia: Yes / No
History of suicide attempt during current course of illness: Yes / No
Baseline profile (on day 1)
PANSS Total score:
PANSS positive subscale score:
PANSS Negative subscale score:
PANSS General Symptom subscale score:
General examination
Weight:
BMI:
Pulse rate:
Blood pressure:
Investigations
Total blood count:
Differential count:
Haemoglobin:
Blood  Urea:
Serum Creatinine:
Blood sugar (F):
Blood sugar (PP):
Fasting Lipid profile
Total cholesterol:
Serum triglyceride:
LDL:
VLDL:
HDL:
Total cholesterol / HDL ratio
TGL / HDL ratio:
Liver function test
Total bilirubin:
SGOT:
SGPT:
Alkaline phosphatise:
Total protein:
At the end of trial period (6 weeks)
PANSS Total score:
PANSS positive subscale score:
PANSS Negative subscale score:
PANSS General Symptom subscale score:
General examination
Weight:
BMI:
Pulse rate:
Blood pressure:
Investigations
Total blood count:
Differential count:
Haemoglobin:
Blood  Urea:
Serum Creatinine:
Blood sugar (F):
Blood sugar (PP):
Fasting Lipid profile
Total cholesterol:
Serum triglyceride:
LDL:
VLDL:
HDL:
Total cholesterol / HDL ratio
TGL / HDL ratio:
Liver function test
Total bilirubin:
SGOT:
SGPT:
Alkaline phosphatase:
Total protein:
Adverse drug reactions check list
Headache Anxiety
Akathisia Nausea
Somnolence Agitation
Insomnia Dyspepsia
Sedation Constipation
Back pain Vomiting
Dizziness Musculoskeletal stiffness
Restlessness Decreased appetite
Hypersalivation Increased appetite
Weight gain Tooth ache
Dry mouth sexual dysfunction
Tremor Dystonia
Rigidity Menstrual irregularities
Total number of ADRs:
APPENDIX – IV
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1 L 3 6 8 9 14 15 17 27 14 11 40 20 16 132 68 60 54 57 21 22 105 110 180 190 230 190 190 178 49 45 100 112 52 45
2 L 3 5 7 9 11 16 18 39 25 17 32 20 11 144 88 42 64 65 24 24 90 94 157 145 185 171 225 230 45 45 95 90 45 47
3 L 2 5 7 9 11 16 18 21 11 10 20 13 10 88 48 36 75 75 27 27 110 108 120 132 132 130 79 85 40 42 79 84 39 36
4 L 2 6 7 10 11 16 17 35 21 15 35 21 20 95 54 50 45 47 17 18 92 99 175 160 141 145 165 154 45 42 61 64 33 30
5 L 3 6 7 9 13 15 18 35 31 30 36 32 30 121 110 105 59 58 22 22 106 98 102 110 180 147 163 152 42 40 106 77 32 30
6 L 1 5 7 10 11 16 18 30 21 15 22 18 15 96 79 52 49 54 18 20 90 95 100 101 160 140 115 115 39 37 78 80 21 23
7 L 3 6 7 9 14 15 17 44 21 10 31 20 10 126 74 39 56 57 22 22 110 99 200 180 200 192 170 176 40 38 100 91 50 48
8 L 1 6 7 10 11 15 18 23 15 12 21 16 13 85 71 66 42 43 16 16 100 101 104 110 173 181 177 183 42 41 96 90 35 33
9 L 3 5 7 9 13 15 17 39 31 18 25 19 11 112 72 52 66 66 23 23 104 98 120 109 154 156 200 221 58 58 50 54 44 44
10 L 2 6 7 9 13 15 18 42 34 30 25 20 18 110 84 71 34 35 13 14 90 85 120 110 115 123 80 85 34 35 65 61 16 22
11 L 4 6 7 9 14 16 18 29 20 10 29 18 10 94 54 33 36 37 14 15 95 100 105 140 163 170 121 139 40 38 60 55 19 12
12 L 3 5 7 9 14 16 18 25 18 15 27 13 11 99 51 34 56 56 20 20 90 93 180 140 160 182 161 150 38 42 100 93 30 23
13 L 2 5 7 10 14 16 18 40 31 21 34 28 15 152 118 51 71 74 20 27 103 92 139 140 112 129 127 132 40 40 25 32 25 29
14 L 3 6 7 9 12 15 18 29 20 11 25 18 10 120 56 42 35 35 14 14 100 92 180 220 180 200 160 182 42 40 29 32 40 36
15 L 2 5 7 10 14 16 18 26 20 10 21 17 10 100 55 35 84 82 29 29 72 69 110 108 160 189 140 139 40 43 88 100 45 32
16 L 3 5 7 9 13 16 18 38 28 25 28 28 25 138 110 100 83 83 30 30 100 156 130 180 149 220 132 188 45 48 46 48 32 35
17 L 3 5 8 10 14 15 17 25 20 11 24 16 10 99 66 42 45 50 16 17 79 108 96 115 100 105 60 60 38 40 50 48 12 15
18 L 3 5 8 9 12 15 17 40 20 14 38 23 14 118 69 48 66 67 23 23 123 121 143 136 166 162 111 121 33 34 45 43 23 23
19 L 2 6 7 10 13 15 17 36 23 22 39 31 26 109 81 66 76 79 28 30 98 110 123 122 145 189 122 156 34 33 49 66 34 34
20 L 4 5 7 9 14 16 18 43 22 20 37 22 18 118 69 48 57 57 22 22 177 189 190 179 123 133 99 87 44 42 34 35 44 42
21 L 3 5 7 9 13 16 17 46 32 21 33 23 13 120 78 44 59 64 22 25 122 156 134 166 144 146 101 98 37 34 44 43 38 37
22 L 4 5 8 9 12 16 18 40 30 21 19 15 13 123 75 55 65 66 22 23 123 112 136 135 166 168 144 144 36 36 100 99 55 52
23 L 3 6 7 9 13 16 18 33 18 12 24 14 10 114 49 40 59 59 20 20 111 102 136 145 169 158 99 103 48 42 56 56 44 44
24 L 4 5 7 9 14 16 18 21 18 10 40 22 14 122 66 45 72 76 26 27 94 98 110 108 145 204 117 174 55 44 54 54 44 46
1 R 4 5 8 9 14 15 17 31 15 10 31 15 10 122 60 36 44 46 17 18 83 105 100 125 168 172 110 100 40 38 52 40 39 23
2 R 2 6 7 9 14 15 18 22 21 20 25 18 15 95 80 60 71 74 28 29 96 92 111 120 150 190 75 140 35 32 100 130 50 28
3 R 4 6 7 9 11 16 18 32 18 11 21 12 10 100 44 30 60 61 23 24 99 100 135 140 190 220 211 200 36 30 102 98 52 60
4 R 2 6 7 9 13 15 17 42 21 11 15 11 11 91 38 34 57 61 23 24 90 100 150 150 180 200 140 172 40 38 80 110 50 72
5 R 1 5 7 10 12 16 18 40 38 22 35 30 24 125 112 89 61 66 21 22 70 91 120 130 150 164 130 152 34 36 90 82 26 15
6 R 2 5 8 9 13 16 18 25 16 13 26 16 14 97 52 44 47 49 18 18 80 100 94 120 165 189 172 180 37 39 95 82 33 15
7 R 1 5 7 10 11 16 18 22 14 12 19 11 11 84 45 39 54 60 19 21 94 100 124 136 100 120 75 82 39 42 56 70 15 12
8 R 2 5 7 9 13 16 17 30 15 10 26 12 10 113 75 44 65 66 25 25 118 120 230 240 170 152 130 159 40 42 90 103 42 25
9 R 3 5 7 10 14 15 18 32 22 16 32 22 12 120 75 56 45 46 16 16 130 119 280 263 220 197 170 187 38 37 110 124 54 33
10 R 2 5 7 10 14 16 18 31 18 12 29 12 11 105 46 40 45 46 16 16 106 92 140 159 179 190 130 143 40 37 113 98 26 18
11 R 3 6 7 9 14 16 18 26 18 16 36 22 10 112 61 50 45 49 18 20 97 112 180 160 176 190 170 182 37 38 97 109 40 29
12 R 2 6 7 9 11 16 18 25 12 10 25 12 9 100 43 34 53 53 20 20 118 130 230 252 170 197 150 163 34 36 81 99 30 25
13 R 3 6 8 9 14 16 18 44 29 12 39 25 16 130 95 45 74 74 28 28 121 104 169 177 174 193 133 149 42 43 106 83 26 16
14 R 2 6 7 9 11 15 18 28 24 19 23 20 20 98 85 64 84 87 31 32 102 97 118 131 145 163 95 120 41 38 85 93 19 12
15 R 2 6 7 9 13 16 17 40 20 7 35 15 9 118 50 33 54 54 19 19 90 81 125 111 163 150 171 175 40 37 90 81 20 24
16 R 2 6 7 9 13 15 18 39 30 22 32 25 21 106 82 65 59 62 22 23 71 83 110 100 143 161 93 102 40 39 71 43 30 15
17 R 3 5 7 9 13 15 17 42 25 14 41 20 15 110 88 46 84 86 28 29 63 89 111 120 153 169 170 185 36 35 112 89 38 45
18 R 3 5 7 9 14 16 18 28 15 8 20 12 9 98 45 34 78 78 28 28 101 110 140 162 153 176 160 171 40 36 97 89 44 53
19 R 2 6 7 10 13 15 18 44 24 12 19 11 8 108 60 45 45 48 17 18 72 85 102 120 136 151 146 154 39 37 84 91 41 35
20 R 2 5 7 10 14 15 18 33 21 12 28 15 7 95 54 35 60 62 21 22 105 130 160 172 171 182 177 169 44 42 84 80 40 36
21 R 3 5 7 9 14 16 18 40 28 12 40 28 11 120 80 44 92 93 32 32 101 110 142 132 189 170 120 112 51 48 90 85 42 46
22 R 3 5 7 9 13 16 18 38 30 24 32 26 18 106 88 66 74 75 28 28 115 112 135 125 112 132 96 94 41 42 88 75 52 49
23 R 2 6 8 10 12 16 18 36 25 8 19 11 7 89 52 36 54 56 19 21 116 120 125 124 142 146 112 100 42 38 66 69 42 41
24 R 4 6 8 9 11 15 17 36 26 16 36 22 13 110 74 44 76 82 29 31 121 156 144 188 154 221 121 144 39 39 88 68 44 55
25 R 2 5 7 9 11 16 17 29 15 9 36 22 14 99 44 30 58 58 22 22 73 81 112 110 113 122 100 79 44 41 56 61 54 55
26 R 3 6 8 10 14 15 17 46 25 22 34 24 21 120 85 67 66 67 25 25 89 99 100 111 98 99 78 77 34 35 56 45 44 55
L-Lurasidone, R-Risperidone
APPENDIX – V
ABBREVIATIONS
CGIS
CYP
DA
DAT
DSM
EPS
H
HDL
5HT
ICD
LDL
NMDA
PANSS
SGOT
SGPT
TGL
VMAT
VLDL
WHO
Clinical Global Impression score
Cytochrome P 450
Dopamine
Dopamine transporter
Diagnostic statistical manual
Extrapyramidal symptoms
Histamine
High density lipoprotein
5-hydroxy tryptamine
International classification of disease
Low density lipoprotein
N- Methyl D- aspartate
Positive and negative syndrome scale
Serum glutamic oxaloacetic
transaminase
Serum glutamic pyruvic transaminase
Triglycerides
Vesicular monoamine transporter
Very low density lipoprotein
World health organization
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